GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases

GeoVax Labs, Inc. is making significant strides with its GEO-MVA Mpox/smallpox vaccine, as global cases rise and the need for pandemic preparedness gains bipartisan support. The European Medicines Agency (EMA) has provided favorable regulatory input, setting the vaccine on an expedited path toward market access. This development not only accelerates GeoVax's focus on regulatory approval and commercialization but also addresses the urgent need for additional MVA-vaccine supply options amidst confirmed Mpox cases across the U.S., Europe, and new outbreaks in Africa.

The company's innovative platform, featuring a development-stage continuous avian cell line process, promises increased production of MVA-based vaccines, quicker response to epidemics, and reduced production costs. David Dodd, GeoVax's Chairman and CEO, highlighted the importance of diversifying stockpile planning, positioning GEO-MVA as a complementary or alternative solution to current single-source options. The recent favorable Scientific Advice from the EMA and the ongoing review of GeoVax's proposal under BARDA’s Rapid Response Partnership Vehicle (RRPV) further expedite the vaccine's readiness, offering a scalable solution to high-consequence threats like smallpox.